AU2009217278B2 - Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism - Google Patents
Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism Download PDFInfo
- Publication number
- AU2009217278B2 AU2009217278B2 AU2009217278A AU2009217278A AU2009217278B2 AU 2009217278 B2 AU2009217278 B2 AU 2009217278B2 AU 2009217278 A AU2009217278 A AU 2009217278A AU 2009217278 A AU2009217278 A AU 2009217278A AU 2009217278 B2 AU2009217278 B2 AU 2009217278B2
- Authority
- AU
- Australia
- Prior art keywords
- autism
- chromosome
- nucleic acid
- cnv
- snp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 91
- 208000020706 Autistic disease Diseases 0.000 title claims description 180
- 206010003805 Autism Diseases 0.000 title claims description 179
- 230000004077 genetic alteration Effects 0.000 title claims description 20
- 231100000118 genetic alteration Toxicity 0.000 title claims description 20
- 238000011282 treatment Methods 0.000 title abstract description 11
- 238000003745 diagnosis Methods 0.000 title description 11
- 208000029560 autism spectrum disease Diseases 0.000 claims abstract description 98
- 238000001514 detection method Methods 0.000 claims abstract description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 105
- 102000039446 nucleic acids Human genes 0.000 claims description 97
- 108020004707 nucleic acids Proteins 0.000 claims description 97
- 210000000349 chromosome Anatomy 0.000 claims description 72
- 210000004027 cell Anatomy 0.000 claims description 70
- 238000004458 analytical method Methods 0.000 claims description 52
- 230000002068 genetic effect Effects 0.000 claims description 49
- 239000000523 sample Substances 0.000 claims description 38
- 108700028369 Alleles Proteins 0.000 claims description 25
- 239000002773 nucleotide Substances 0.000 claims description 24
- 125000003729 nucleotide group Chemical group 0.000 claims description 24
- 101100495925 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr3 gene Proteins 0.000 claims description 23
- 238000009396 hybridization Methods 0.000 claims description 19
- 238000012217 deletion Methods 0.000 claims description 17
- 230000037430 deletion Effects 0.000 claims description 17
- 108091033319 polynucleotide Proteins 0.000 claims description 13
- 102000040430 polynucleotide Human genes 0.000 claims description 13
- 239000002157 polynucleotide Substances 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 229920002477 rna polymer Polymers 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 9
- 108090000623 proteins and genes Proteins 0.000 description 113
- 108020004414 DNA Proteins 0.000 description 40
- 108090000765 processed proteins & peptides Proteins 0.000 description 38
- 230000014509 gene expression Effects 0.000 description 37
- 238000003908 quality control method Methods 0.000 description 31
- 238000012098 association analyses Methods 0.000 description 29
- 102000004196 processed proteins & peptides Human genes 0.000 description 27
- 239000013598 vector Substances 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 23
- 102100025332 Cadherin-9 Human genes 0.000 description 22
- 101710097558 Cadherin-9 Proteins 0.000 description 22
- 229920001184 polypeptide Polymers 0.000 description 22
- 238000013459 approach Methods 0.000 description 21
- 239000003550 marker Substances 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 21
- 230000000295 complement effect Effects 0.000 description 20
- 238000011161 development Methods 0.000 description 20
- 238000003205 genotyping method Methods 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 230000018109 developmental process Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 108091034117 Oligonucleotide Proteins 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 230000001537 neural effect Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 108050007957 Cadherin Proteins 0.000 description 11
- 102100022758 Glutamate receptor ionotropic, kainate 2 Human genes 0.000 description 11
- 101000903346 Homo sapiens Glutamate receptor ionotropic, kainate 2 Proteins 0.000 description 11
- 101000903313 Homo sapiens Glutamate receptor ionotropic, kainate 5 Proteins 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 102100024158 Cadherin-10 Human genes 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 101000762229 Homo sapiens Cadherin-10 Proteins 0.000 description 8
- 102100021582 Neurexin-1-beta Human genes 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 8
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 8
- 102000000905 Cadherin Human genes 0.000 description 7
- 102100040499 Contactin-associated protein-like 2 Human genes 0.000 description 7
- 101000996111 Homo sapiens Neuroligin-4, X-linked Proteins 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 102100034441 Neuroligin-4, X-linked Human genes 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000006735 deficit Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000011988 family based association test Methods 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000007372 neural signaling Effects 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000009261 transgenic effect Effects 0.000 description 7
- 238000011830 transgenic mouse model Methods 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 101001108436 Homo sapiens Neurexin-1 Proteins 0.000 description 6
- 101001108433 Homo sapiens Neurexin-1-beta Proteins 0.000 description 6
- 238000003491 array Methods 0.000 description 6
- 238000012093 association test Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 230000008506 pathogenesis Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 102100036364 Cadherin-2 Human genes 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 101000714537 Homo sapiens Cadherin-2 Proteins 0.000 description 5
- 101000749877 Homo sapiens Contactin-associated protein-like 2 Proteins 0.000 description 5
- 101000603172 Homo sapiens Neuroligin-3 Proteins 0.000 description 5
- 108091029795 Intergenic region Proteins 0.000 description 5
- -1 NRXJ N Proteins 0.000 description 5
- 102100038940 Neuroligin-3 Human genes 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 230000006854 communication Effects 0.000 description 5
- 238000004891 communication Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229930024421 Adenine Natural products 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 102100024340 Contactin-4 Human genes 0.000 description 4
- 241000557626 Corvus corax Species 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 4
- 102100032999 Integrin beta-3 Human genes 0.000 description 4
- 108700011259 MicroRNAs Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102100038992 Neuroligin-1 Human genes 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 102100030681 SH3 and multiple ankyrin repeat domains protein 3 Human genes 0.000 description 4
- 101710101741 SH3 and multiple ankyrin repeat domains protein 3 Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000019522 cellular metabolic process Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000001054 cortical effect Effects 0.000 description 4
- 230000002559 cytogenic effect Effects 0.000 description 4
- 229940104302 cytosine Drugs 0.000 description 4
- 238000009510 drug design Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 238000010197 meta-analysis Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229940113082 thymine Drugs 0.000 description 4
- 241000972773 Aulopiformes Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102100022481 Cadherin-22 Human genes 0.000 description 3
- 208000031404 Chromosome Aberrations Diseases 0.000 description 3
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 description 3
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102100040667 F-box only protein 33 Human genes 0.000 description 3
- 108091007098 FBXO33 Proteins 0.000 description 3
- 102000017707 GABRB3 Human genes 0.000 description 3
- 101000899455 Homo sapiens Cadherin-22 Proteins 0.000 description 3
- 101000909504 Homo sapiens Contactin-4 Proteins 0.000 description 3
- 101001073597 Homo sapiens Gamma-aminobutyric acid receptor subunit beta-3 Proteins 0.000 description 3
- 101001033173 Homo sapiens Methyltransferase-like protein 22 Proteins 0.000 description 3
- 101000603239 Homo sapiens Neuroligin-1 Proteins 0.000 description 3
- 101000982057 Homo sapiens Unconventional myosin-XVI Proteins 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 3
- 102100038290 Methyltransferase-like protein 22 Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000012202 Pervasive developmental disease Diseases 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 102100026677 Unconventional myosin-XVI Human genes 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 230000001364 causal effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000007877 drug screening Methods 0.000 description 3
- 210000005153 frontal cortex Anatomy 0.000 description 3
- 208000016361 genetic disease Diseases 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000003765 sex chromosome Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000013517 stratification Methods 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000001755 vocal effect Effects 0.000 description 3
- 238000002424 x-ray crystallography Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- RFBVBRVVOPAAFS-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)-1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2CCN1C(CO)(CO)C2=O RFBVBRVVOPAAFS-UHFFFAOYSA-N 0.000 description 2
- 102100033639 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 101800000263 Acidic protein Proteins 0.000 description 2
- 102100035553 Autism susceptibility gene 2 protein Human genes 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 101710196887 Cadherin-10 Proteins 0.000 description 2
- 102100024156 Cadherin-12 Human genes 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 101710168458 Contactin-associated protein-like 2 Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- 208000001914 Fragile X syndrome Diseases 0.000 description 2
- 102100030540 Gap junction alpha-5 protein Human genes 0.000 description 2
- 102100022193 Glutamate receptor ionotropic, delta-1 Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000874361 Homo sapiens Autism susceptibility gene 2 protein Proteins 0.000 description 2
- 101000762238 Homo sapiens Cadherin-12 Proteins 0.000 description 2
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 2
- 101000726548 Homo sapiens Gap junction alpha-5 protein Proteins 0.000 description 2
- 101000900493 Homo sapiens Glutamate receptor ionotropic, delta-1 Proteins 0.000 description 2
- 101000619663 Homo sapiens Leucine-rich repeat-containing protein 1 Proteins 0.000 description 2
- 101001052076 Homo sapiens Maltase-glucoamylase Proteins 0.000 description 2
- 101000741879 Homo sapiens POTE ankyrin domain family member A Proteins 0.000 description 2
- 101000735377 Homo sapiens Protocadherin-7 Proteins 0.000 description 2
- 101000825253 Homo sapiens Sperm protein associated with the nucleus on the X chromosome A Proteins 0.000 description 2
- 101000892344 Homo sapiens Transmembrane protein 185A Proteins 0.000 description 2
- 101000841325 Homo sapiens Urotensin-2 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 102100022237 Leucine-rich repeat-containing protein 1 Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100298534 Mus musculus Prnp gene Proteins 0.000 description 2
- 101710203761 Neurexin-1 Proteins 0.000 description 2
- 102000005608 Neuronal Cell Adhesion Molecules Human genes 0.000 description 2
- 108010059604 Neuronal Cell Adhesion Molecules Proteins 0.000 description 2
- 102100038749 POTE ankyrin domain family member A Human genes 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 2
- 108010019674 Proto-Oncogene Proteins c-sis Proteins 0.000 description 2
- 102100034941 Protocadherin-7 Human genes 0.000 description 2
- 208000006289 Rett Syndrome Diseases 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 102100022327 Sperm protein associated with the nucleus on the X chromosome A Human genes 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 102100040666 Transmembrane protein 185A Human genes 0.000 description 2
- 208000037280 Trisomy Diseases 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- 102100029097 Urotensin-2 Human genes 0.000 description 2
- 210000001766 X chromosome Anatomy 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000003116 impacting effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000012750 in vivo screening Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000007838 multiplex ligation-dependent probe amplification Methods 0.000 description 2
- 230000007472 neurodevelopment Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000001209 resonance light scattering Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- IPVFGAYTKQKGBM-BYPJNBLXSA-N 1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 IPVFGAYTKQKGBM-BYPJNBLXSA-N 0.000 description 1
- 102100030390 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 Human genes 0.000 description 1
- 102100040458 2',3'-cyclic-nucleotide 3'-phosphodiesterase Human genes 0.000 description 1
- 101150055869 25 gene Proteins 0.000 description 1
- 102100038049 5'-AMP-activated protein kinase subunit beta-2 Human genes 0.000 description 1
- 102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 102100034609 Ankyrin repeat domain-containing protein 17 Human genes 0.000 description 1
- 102100036817 Ankyrin-3 Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 102100027705 Astrotactin-2 Human genes 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
- 102100029844 B box and SPRY domain-containing protein Human genes 0.000 description 1
- 102100032481 B-cell CLL/lymphoma 9 protein Human genes 0.000 description 1
- 102100035901 BICD family-like cargo adapter 1 Human genes 0.000 description 1
- 102000015347 COP1 Human genes 0.000 description 1
- 108060001826 COP1 Proteins 0.000 description 1
- 102100027674 CTD small phosphatase-like protein Human genes 0.000 description 1
- 102100024155 Cadherin-11 Human genes 0.000 description 1
- 102100024154 Cadherin-13 Human genes 0.000 description 1
- 102100022529 Cadherin-19 Human genes 0.000 description 1
- 102100025331 Cadherin-8 Human genes 0.000 description 1
- 102100031239 Chromodomain-helicase-DNA-binding protein 1-like Human genes 0.000 description 1
- 102100038164 Chromodomain-helicase-DNA-binding protein 9 Human genes 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 102100031552 Coactosin-like protein Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 101710107714 Contactin-4 Proteins 0.000 description 1
- 102100040495 Contactin-associated protein-like 5 Human genes 0.000 description 1
- 102100027475 Cytochrome c oxidase assembly protein COX18, mitochondrial Human genes 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 102100024352 Dedicator of cytokinesis protein 4 Human genes 0.000 description 1
- FHZPGIUBXYVUOY-VWGYHWLBSA-N Dermorphin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)C1=CC=C(O)C=C1 FHZPGIUBXYVUOY-VWGYHWLBSA-N 0.000 description 1
- 101800002242 Dermorphin Proteins 0.000 description 1
- 208000035976 Developmental Disabilities Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100024099 Disks large homolog 1 Human genes 0.000 description 1
- 102100031250 Disks large-associated protein 1 Human genes 0.000 description 1
- 102100035372 DmX-like protein 1 Human genes 0.000 description 1
- 101100084900 Drosophila melanogaster Rpn11 gene Proteins 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 102100022207 E3 ubiquitin-protein ligase parkin Human genes 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102100026082 F-box only protein 40 Human genes 0.000 description 1
- 102100026167 Fez family zinc finger protein 2 Human genes 0.000 description 1
- 102100035047 Flavin-containing monooxygenase 5 Human genes 0.000 description 1
- 102100028875 Formylglycine-generating enzyme Human genes 0.000 description 1
- 108010032606 Fragile X Mental Retardation Protein Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 102100021021 Golgin subfamily A member 6-like protein 2 Human genes 0.000 description 1
- 102100041033 Golgin subfamily B member 1 Human genes 0.000 description 1
- 102100028484 HEAT repeat-containing protein 5B Human genes 0.000 description 1
- 102100034684 Haloacid dehalogenase-like hydrolase domain-containing protein 3 Human genes 0.000 description 1
- 102100040414 Heat shock transcription factor, X-linked Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000583063 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 Proteins 0.000 description 1
- 101000742799 Homo sapiens 5'-AMP-activated protein kinase subunit beta-2 Proteins 0.000 description 1
- 101000986621 Homo sapiens ATP-binding cassette sub-family C member 6 Proteins 0.000 description 1
- 101000924481 Homo sapiens Ankyrin repeat domain-containing protein 17 Proteins 0.000 description 1
- 101000928342 Homo sapiens Ankyrin-3 Proteins 0.000 description 1
- 101000936743 Homo sapiens Astrotactin-2 Proteins 0.000 description 1
- 101000864323 Homo sapiens B box and SPRY domain-containing protein Proteins 0.000 description 1
- 101000798495 Homo sapiens B-cell CLL/lymphoma 9 protein Proteins 0.000 description 1
- 101000873626 Homo sapiens BICD family-like cargo adapter 1 Proteins 0.000 description 1
- 101000725950 Homo sapiens CTD small phosphatase-like protein Proteins 0.000 description 1
- 101000762236 Homo sapiens Cadherin-11 Proteins 0.000 description 1
- 101000762243 Homo sapiens Cadherin-13 Proteins 0.000 description 1
- 101000899410 Homo sapiens Cadherin-19 Proteins 0.000 description 1
- 101000935095 Homo sapiens Cadherin-8 Proteins 0.000 description 1
- 101000882994 Homo sapiens Carbohydrate sulfotransferase 5 Proteins 0.000 description 1
- 101000777053 Homo sapiens Chromodomain-helicase-DNA-binding protein 1-like Proteins 0.000 description 1
- 101000883548 Homo sapiens Chromodomain-helicase-DNA-binding protein 9 Proteins 0.000 description 1
- 101000940352 Homo sapiens Coactosin-like protein Proteins 0.000 description 1
- 101000749883 Homo sapiens Contactin-associated protein-like 5 Proteins 0.000 description 1
- 101000725462 Homo sapiens Cytochrome c oxidase assembly protein COX18, mitochondrial Proteins 0.000 description 1
- 101001052955 Homo sapiens Dedicator of cytokinesis protein 4 Proteins 0.000 description 1
- 101001053984 Homo sapiens Disks large homolog 1 Proteins 0.000 description 1
- 101000844784 Homo sapiens Disks large-associated protein 1 Proteins 0.000 description 1
- 101000951365 Homo sapiens Disks large-associated protein 5 Proteins 0.000 description 1
- 101000804531 Homo sapiens DmX-like protein 1 Proteins 0.000 description 1
- 101000913308 Homo sapiens F-box only protein 40 Proteins 0.000 description 1
- 101000912440 Homo sapiens Fez family zinc finger protein 2 Proteins 0.000 description 1
- 101001022794 Homo sapiens Flavin-containing monooxygenase 5 Proteins 0.000 description 1
- 101000648611 Homo sapiens Formylglycine-generating enzyme Proteins 0.000 description 1
- 101001075380 Homo sapiens Golgin subfamily A member 6-like protein 2 Proteins 0.000 description 1
- 101001039321 Homo sapiens Golgin subfamily B member 1 Proteins 0.000 description 1
- 101000839975 Homo sapiens HEAT repeat-containing protein 5B Proteins 0.000 description 1
- 101000872853 Homo sapiens Haloacid dehalogenase-like hydrolase domain-containing protein 3 Proteins 0.000 description 1
- 101001037907 Homo sapiens Heat shock transcription factor, X-linked Proteins 0.000 description 1
- 101001037204 Homo sapiens Hydrocephalus-inducing protein homolog Proteins 0.000 description 1
- 101001011421 Homo sapiens IQ domain-containing protein E Proteins 0.000 description 1
- 101001134447 Homo sapiens Inactive pancreatic lipase-related protein 1 Proteins 0.000 description 1
- 101001056469 Homo sapiens Keratin, type II cytoskeletal 3 Proteins 0.000 description 1
- 101100181431 Homo sapiens LCE3D gene Proteins 0.000 description 1
- 101100181432 Homo sapiens LCE3E gene Proteins 0.000 description 1
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 description 1
- 101000620894 Homo sapiens Lysophosphatidic acid phosphatase type 6 Proteins 0.000 description 1
- 101001038491 Homo sapiens Lysozyme g-like protein 2 Proteins 0.000 description 1
- 101000969961 Homo sapiens Neurexin-3 Proteins 0.000 description 1
- 101000969963 Homo sapiens Neurexin-3-beta Proteins 0.000 description 1
- 101000634529 Homo sapiens Nuclear pore-associated protein 1 Proteins 0.000 description 1
- 101001130823 Homo sapiens Oxysterol-binding protein-related protein 10 Proteins 0.000 description 1
- 101000986765 Homo sapiens Oxytocin receptor Proteins 0.000 description 1
- 101001009074 Homo sapiens Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Proteins 0.000 description 1
- 101000808590 Homo sapiens Probable ubiquitin carboxyl-terminal hydrolase FAF-Y Proteins 0.000 description 1
- 101000619617 Homo sapiens Proline-rich membrane anchor 1 Proteins 0.000 description 1
- 101000946275 Homo sapiens Protein CLEC16A Proteins 0.000 description 1
- 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 description 1
- 101000601855 Homo sapiens Protocadherin-1 Proteins 0.000 description 1
- 101001035676 Homo sapiens Pseudouridine-5'-phosphatase Proteins 0.000 description 1
- 101000825960 Homo sapiens R-spondin-3 Proteins 0.000 description 1
- 101001076721 Homo sapiens RNA-binding protein 38 Proteins 0.000 description 1
- 101000742932 Homo sapiens Retinol dehydrogenase 16 Proteins 0.000 description 1
- 101000825912 Homo sapiens SAYSvFN domain-containing protein 1 Proteins 0.000 description 1
- 101000663831 Homo sapiens SH3 and PX domain-containing protein 2A Proteins 0.000 description 1
- 101000703464 Homo sapiens SH3 and multiple ankyrin repeat domains protein 2 Proteins 0.000 description 1
- 101000864837 Homo sapiens SIN3-HDAC complex-associated factor Proteins 0.000 description 1
- 101000851696 Homo sapiens Steroid hormone receptor ERR2 Proteins 0.000 description 1
- 101000839323 Homo sapiens Synaptotagmin-7 Proteins 0.000 description 1
- 101000852716 Homo sapiens T-cell immunomodulatory protein Proteins 0.000 description 1
- 101000831834 Homo sapiens Transmembrane protein 231 Proteins 0.000 description 1
- 101000764644 Homo sapiens Trimethyllysine dioxygenase, mitochondrial Proteins 0.000 description 1
- 101000800807 Homo sapiens Tumor necrosis factor alpha-induced protein 8 Proteins 0.000 description 1
- 101000744939 Homo sapiens Zinc finger protein 492 Proteins 0.000 description 1
- 101000723601 Homo sapiens Zinc finger protein 528 Proteins 0.000 description 1
- 101000723613 Homo sapiens Zinc finger protein 534 Proteins 0.000 description 1
- 101000743802 Homo sapiens Zinc finger protein 675 Proteins 0.000 description 1
- 101000743810 Homo sapiens Zinc finger protein 681 Proteins 0.000 description 1
- 101000772560 Homo sapiens Zinc finger transcription factor Trps1 Proteins 0.000 description 1
- 101000978006 Homo sapiens cAMP-dependent protein kinase inhibitor beta Proteins 0.000 description 1
- 102100040204 Hydrocephalus-inducing protein homolog Human genes 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102100029840 IQ domain-containing protein E Human genes 0.000 description 1
- 102100033358 Inactive pancreatic lipase-related protein 1 Human genes 0.000 description 1
- 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 1
- 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
- 102100025759 Keratin, type II cytoskeletal 3 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 102100024572 Late cornified envelope protein 3D Human genes 0.000 description 1
- 102100024575 Late cornified envelope protein 3E Human genes 0.000 description 1
- 241001487991 Lettuce chlorosis virus Species 0.000 description 1
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 description 1
- 102100022916 Lysophosphatidic acid phosphatase type 6 Human genes 0.000 description 1
- 102100040286 Lysozyme g-like protein 2 Human genes 0.000 description 1
- 101700028140 MYO1D Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 1
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101150118742 NP gene Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102100021310 Neurexin-3 Human genes 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102100029048 Nuclear pore-associated protein 1 Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102100031469 Oxysterol-binding protein-related protein 10 Human genes 0.000 description 1
- 102100028139 Oxytocin receptor Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
- 101710133394 POU domain, class 3, transcription factor 2 Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102100027376 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102100038600 Probable ubiquitin carboxyl-terminal hydrolase FAF-Y Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100022184 Proline-rich membrane anchor 1 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100034718 Protein CLEC16A Human genes 0.000 description 1
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
- 102100037551 Protocadherin-1 Human genes 0.000 description 1
- 102100036386 Protocadherin-10 Human genes 0.000 description 1
- 101710158923 Protocadherin-10 Proteins 0.000 description 1
- 108700040559 Protocadherins Proteins 0.000 description 1
- 102100039391 Pseudouridine-5'-phosphatase Human genes 0.000 description 1
- 102100022766 R-spondin-3 Human genes 0.000 description 1
- 102100025859 RNA-binding protein 38 Human genes 0.000 description 1
- 208000033639 Rare pervasive developmental disease Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100021289 Regulator of G-protein signaling 20 Human genes 0.000 description 1
- 101710148117 Regulator of G-protein signaling 20 Proteins 0.000 description 1
- 102100038057 Retinol dehydrogenase 16 Human genes 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 102100022776 SAYSvFN domain-containing protein 1 Human genes 0.000 description 1
- 102100038875 SH3 and PX domain-containing protein 2A Human genes 0.000 description 1
- 102100030680 SH3 and multiple ankyrin repeat domains protein 2 Human genes 0.000 description 1
- 102100030066 SIN3-HDAC complex-associated factor Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 102100036831 Steroid hormone receptor ERR2 Human genes 0.000 description 1
- 102100023532 Synaptic functional regulator FMR1 Human genes 0.000 description 1
- 102100028197 Synaptotagmin-7 Human genes 0.000 description 1
- 102100036378 T-cell immunomodulatory protein Human genes 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100024183 Transmembrane protein 231 Human genes 0.000 description 1
- 102100026223 Trimethyllysine dioxygenase, mitochondrial Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100033649 Tumor necrosis factor alpha-induced protein 8 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102000018390 Ubiquitin-Specific Proteases Human genes 0.000 description 1
- 108010066496 Ubiquitin-Specific Proteases Proteins 0.000 description 1
- 102100036638 Unconventional myosin-Id Human genes 0.000 description 1
- 206010049644 Williams syndrome Diseases 0.000 description 1
- 108700029631 X-Linked Genes Proteins 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- 102100039969 Zinc finger protein 492 Human genes 0.000 description 1
- 102100027803 Zinc finger protein 528 Human genes 0.000 description 1
- 102100027859 Zinc finger protein 534 Human genes 0.000 description 1
- 102100039039 Zinc finger protein 675 Human genes 0.000 description 1
- 102100039053 Zinc finger protein 681 Human genes 0.000 description 1
- 102100030619 Zinc finger transcription factor Trps1 Human genes 0.000 description 1
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000012443 analytical study Methods 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 102100023516 cAMP-dependent protein kinase inhibitor beta Human genes 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 230000017484 calcium-dependent cell-cell adhesion Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000023402 cell communication Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000008133 cognitive development Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- YUZILKLGVPUFOT-YHPRVSEPSA-L disodium;5-[(6-anilino-4-oxo-1h-1,3,5-triazin-2-yl)amino]-2-[(e)-2-[4-[(6-anilino-4-oxo-1h-1,3,5-triazin-2-yl)amino]-2-sulfonatophenyl]ethenyl]benzenesulfonate Chemical compound [Na+].[Na+].C=1C=C(\C=C\C=2C(=CC(NC=3NC(NC=4C=CC=CC=4)=NC(=O)N=3)=CC=2)S([O-])(=O)=O)C(S(=O)(=O)[O-])=CC=1NC(N1)=NC(=O)N=C1NC1=CC=CC=C1 YUZILKLGVPUFOT-YHPRVSEPSA-L 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 238000012248 genetic selection Methods 0.000 description 1
- 210000002980 germ line cell Anatomy 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 108090001100 neuroligin 1 Proteins 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 230000023362 neuron cell-cell adhesion Effects 0.000 description 1
- 230000005015 neuronal process Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 238000003068 pathway analysis Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000012107 replication analysis Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000008184 synaptic development Effects 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 101150061422 yip5 gene Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3013608P | 2008-02-20 | 2008-02-20 | |
| US61/030,136 | 2008-02-20 | ||
| US10716308P | 2008-10-21 | 2008-10-21 | |
| US61/107,163 | 2008-10-21 | ||
| PCT/US2009/034784 WO2009105718A1 (en) | 2008-02-20 | 2009-02-20 | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2009217278A1 AU2009217278A1 (en) | 2009-08-27 |
| AU2009217278B2 true AU2009217278B2 (en) | 2015-08-20 |
Family
ID=40985948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009217278A Ceased AU2009217278B2 (en) | 2008-02-20 | 2009-02-20 | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9783851B2 (https=) |
| EP (1) | EP2257644B1 (https=) |
| JP (1) | JP6078211B2 (https=) |
| AU (1) | AU2009217278B2 (https=) |
| CA (1) | CA2716375C (https=) |
| WO (1) | WO2009105718A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0918868B8 (pt) | 2008-09-18 | 2021-05-25 | Naurex Inc | compostos moduladores do receptor de nmda e composições compreendendo os mesmos |
| JP5881420B2 (ja) * | 2008-11-12 | 2016-03-09 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション | 自閉症関連遺伝子マーカー |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| US8772242B2 (en) | 2009-10-26 | 2014-07-08 | Thomas Julius Borody | Therapy for enteric infections |
| CA2807505A1 (en) * | 2010-08-24 | 2012-03-01 | The Children's Hospital Of Philadelphia | Association of rare recurrent genetic variations to attention-deficit, hyperactivity disorder (adhd) and methods of use thereof for the diagnosis and treatment of the same |
| CA2834286A1 (en) * | 2011-04-27 | 2012-11-01 | Northwestern University | Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders |
| WO2012173809A2 (en) * | 2011-06-02 | 2012-12-20 | Ehli Erik | Method of identifying de novo copy number variants (cnv) using mz twins discordant for attention problems/disorders |
| CA2798906A1 (en) * | 2011-12-22 | 2013-06-22 | Mohammed Uddin | Genome-wide detection of genomic rearrangements and use of genomic rearrangements to diagnose genetic disease |
| US20130210657A1 (en) * | 2012-01-25 | 2013-08-15 | The Hospital For Sick Children | Method of Determining Risk of Autism Spectrum Disorder |
| AU2013230045A1 (en) * | 2012-03-05 | 2014-09-11 | Berg Llc | Compositions and methods for diagnosis and treatment of pervasive developmental disorder |
| JP2015510756A (ja) * | 2012-03-09 | 2015-04-13 | アンテグラージェン | 自閉症のリスクを評価するため遺伝子型決定テスト |
| WO2013139861A1 (en) | 2012-03-20 | 2013-09-26 | Luc Montagnier | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| MX357392B (es) | 2012-04-02 | 2018-07-06 | Berg Llc | Ensayos basados en interrogatorios celulares y uso de los mismos. |
| WO2014012144A1 (en) * | 2012-07-20 | 2014-01-23 | The University Of Melbourne | Method of diagnosing or prognosing a neurological disorder |
| JP2016506962A (ja) | 2013-01-29 | 2016-03-07 | ノーレックス, インコーポレイテッドNaurex, Inc. | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
| PE20151416A1 (es) | 2013-01-29 | 2015-10-10 | Naurex Inc | Moduladores de receptores nmda de espiro-lactama y sus usos |
| KR102410989B1 (ko) | 2013-01-29 | 2022-06-17 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| EP2951186B1 (en) | 2013-01-29 | 2018-07-25 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| US9758525B2 (en) | 2013-01-29 | 2017-09-12 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| US11219617B2 (en) | 2014-05-30 | 2022-01-11 | The Children's Hospital Of Philadelphia | Methods of diagnosing and treating autism |
| CN114203296B (zh) | 2014-09-11 | 2025-10-17 | 布普格生物制药公司 | 基于患者数据的用于健康护理诊断和治疗的贝叶斯因果关系网络模型 |
| WO2016057810A1 (en) * | 2014-10-08 | 2016-04-14 | The Broad Institute, Inc. | Markers for assessing risk of developing or having obsessive compulsive disorder |
| WO2016109449A1 (en) * | 2014-12-29 | 2016-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of diagnosing autism spectrum disorders |
| PL4023222T3 (pl) | 2015-09-08 | 2025-03-24 | The Children's Hospital Of Philadelphia | Nieselektywny aktywator metabotropowych receptorów glutaminianu do leczenia zespołu 22q |
| PE20190174A1 (es) | 2016-05-19 | 2019-02-01 | Aptinyx Inc | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| KR102465758B1 (ko) | 2016-08-01 | 2022-11-09 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| WO2018026798A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda modulators and methods of using same |
| AU2017306158B2 (en) | 2016-08-01 | 2021-10-14 | Aptinyx Inc. | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof |
| IL286107B2 (en) | 2016-08-01 | 2024-09-01 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and usesthereof |
| JP7036792B2 (ja) | 2016-08-01 | 2022-03-15 | アプティニックス インコーポレイテッド | スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用 |
| PE20210455A1 (es) | 2018-01-31 | 2021-03-08 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactama y usos de los mismos |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060194201A1 (en) * | 2002-10-10 | 2006-08-31 | Jean-Pierre Fryns | Autism gene |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003052086A1 (en) * | 2001-12-14 | 2003-06-26 | President And Fellows Of Harvard College | Immune related neuronal receptors and therapeutic uses thereof |
-
2009
- 2009-02-20 WO PCT/US2009/034784 patent/WO2009105718A1/en not_active Ceased
- 2009-02-20 CA CA2716375A patent/CA2716375C/en active Active
- 2009-02-20 EP EP09713119.7A patent/EP2257644B1/en active Active
- 2009-02-20 AU AU2009217278A patent/AU2009217278B2/en not_active Ceased
- 2009-02-20 US US12/918,508 patent/US9783851B2/en active Active
- 2009-02-20 JP JP2010547822A patent/JP6078211B2/ja not_active Expired - Fee Related
-
2017
- 2017-10-09 US US15/727,868 patent/US20180148786A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060194201A1 (en) * | 2002-10-10 | 2006-08-31 | Jean-Pierre Fryns | Autism gene |
Also Published As
| Publication number | Publication date |
|---|---|
| US20110207124A1 (en) | 2011-08-25 |
| CA2716375A1 (en) | 2009-08-27 |
| WO2009105718A1 (en) | 2009-08-27 |
| US20180148786A1 (en) | 2018-05-31 |
| EP2257644A1 (en) | 2010-12-08 |
| CA2716375C (en) | 2018-05-29 |
| JP2011512163A (ja) | 2011-04-21 |
| EP2257644A4 (en) | 2011-07-06 |
| AU2009217278A1 (en) | 2009-08-27 |
| US9783851B2 (en) | 2017-10-10 |
| EP2257644B1 (en) | 2015-06-24 |
| JP6078211B2 (ja) | 2017-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009217278B2 (en) | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism | |
| AU2017201900B2 (en) | Association of rare recurrent genetic variations to attention-deficit, hyperactivity disorder (adhd) and methods of use thereof for the diagnosis and treatment of the same | |
| US20150051114A1 (en) | Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets | |
| US20140315992A1 (en) | Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism | |
| US20260022420A1 (en) | Genomic alterations associated with schizophrenia and methods of use thereof for the diagnosis and treatment of the same | |
| WO2012037116A2 (en) | Common and rare genetic variations associated with common variable immunodeficiency (cvid) and methods of use thereof for the treatment and diagnosis of the same | |
| EP3149211A1 (en) | Genetic alterations associated with autism and autistic phenotype and methods of diagnosing and treating autism | |
| US20230357849A1 (en) | Genetic alterations associated with eosinophilic esophagitis and methods of use thereof for the diagnosis and treatment of disease | |
| WO2013142286A1 (en) | Genetic alterations associated with autism and the autistic phenotype in the israeli population and methods of use thereof for the diagnosis and treatment of autism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ GENETIC ALTERATIONS ASSOCIATED WITH AUTISM AND THE AUTISTIC PHENOTYPE AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF AUTISM |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |